Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PF-08046054 by Pfizer for Ovarian Cancer: Likelihood of Approval
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
PF-08046054 by Pfizer for Melanoma: Likelihood of Approval
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...
PF-08046054 by Pfizer for Solid Tumor: Likelihood of Approval
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
PF-08046054 by Pfizer for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
PF-08046054 by Pfizer for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
PF-08046054 by Pfizer for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to...
PF-08046054 by Pfizer for Gastric Cancer: Likelihood of Approval
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
PF-08046054 by Pfizer for Non-Small Cell Lung Cancer: Likelihood of Approval
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...